^
    Back
    Association details:
    Biomarker:ERBB3 mutation
    Cancer:Gallbladder Cancer
    Drug:lapatinib (EGFR inhibitor, HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    South Asian J Cancer
    Title:

    Genomic Landscape and Targeted Treatment of Gallbladder Cancer: Results of a First Ongoing Prospective Study

    Published date:
    12/14/2020
    Excerpt:
    ...patients of unresectable and/or metastatic GBC of age ≥18 years were enrolled. Three patients with ERBB3 mutations showed response to lapatinib-capecitabine.
    Secondary therapy:
    capecitabine
    DOI:
    10.1055/s-0040-1721180